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Abstract We developed and validated an online ques-
tionnaire to document familial cancer history, in order to
facilitate the detection of persons with a familial or her-
editary colorectal cancer (CRC) risk. The development of
the self-administered online questionnaire for the assess-
ment of familial and hereditary CRC risk was based on
nationwide criteria for referral to genetic specialists due to
a Lynch syndrome suspicion, as well as existing criteria for
surveillance colonoscopies because of an increased risk of
familial CRC. The questionnaire was validated at a private
colonoscopy center. Patients scheduled for colonoscopy
were enrolled (n = 150). Performance of the questionnaire
was assessed by comparing referrals based on question-
naire data against referral decisions based on full pedigree
data. In a second validation phase, referrals based on
questionnaire data were compared with referrals based on
data collected in a telephone interview. We also calculated
inter-observer agreement in referral decisions. In the first
validation phase, the questionnaire had a sensitivity of
90 % (95 % CI 55–98 %) at a specificity of 98 % (95 % CI
87–100 %) in identifying persons qualifying for referral. In
the second validation phase, sensitivity was 100 % (95 %
CI 63–100) at a specificity of 97 % (95 % CI 91–99 %). In
both validation phases an inter-observer agreement of
100 % in referral decisions was achieved. The online
questionnaire has a high sensitivity and specificity in
identifying persons qualifying for referral because of sus-
pected Lynch syndrome or familial CRC. Implementation
of this tool in colonoscopy clinics can facilitate the de-
tection of patients with hereditary or familial CRC.
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Introduction
Colorectal cancer (CRC) is the second most prevalent type
of cancer in the Netherlands with more than 13.000 newly
diagnosed patients per year [1]. The lifetime risk of de-
veloping CRC in a Western population is 5–6 % [1–3]. Of
all CRC cases, 15–20 % are related to familial or heredi-
tary factors [4–6].
The most common form of inherited CRC is Lynch
syndrome, which comprises 2–4 % of all CRC cases [7].
This syndrome is caused by an inherited mutation in one of
the mismatch repair genes and is characterized by a pre-
disposition to develop CRC and several extra-intestinal
malignancies, such as endometrial, gastric and ovarian
cancer, at a relatively young age [8, 9]. Lynch syndrome is
usually suspected based on the internationally used
Amsterdam I and II criteria and the Revised Bethesda
criteria [10, 11]. Other hereditary types of CRC include
several polyposis syndromes, such as familial adenomatous
polyposis and MUTYH-associated polyposis.
In familial CRC patients no genetic mutation can be
found. The definition of this syndrome is based on the
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number and age at diagnosis of relatives with CRC. Pa-
tients who are suspected of having an inherited CRC syn-
drome in whom no genetic mutation is found can also be
referred to as familial CRC patients [10, 11]. These patients
have a threefold or higher risk of developing CRC [10, 11].
International guidelines recommend surveillance colono-
scopies for both patients with familial CRC or Lynch syn-
drome [10–13]. Strict surveillance can reduce morbidity and
mortality from CRC by up to 80 % [13–15]. Patients with an
increased CRC risk are also advised to warn their relatives,
who can subsequently consult a clinical geneticist for
evaluation and surveillance recommendations. Additionally,
if Lynch syndrome is diagnosed in a patient with CRC,
surgical treatment might be adjusted; usually a subtotal
colectomy is advised instead of a partial resection [16].
Lynch syndrome and familial CRC often go unrecog-
nized by physicians and patients [6, 17–24]. Many physi-
cians seem to be limited in their ability to apply criteria for
assessing familial risk and surveillance strategies, and they
do not seem to sufficiently explore family history [17–20].
Most CRC patients and their relatives do not themselves
have sufficient information and knowledge to assess their
eligibility for genetic referral [21, 22]. As a consequence,
only a small proportion of CRC patients and their relatives
who would qualify for referral is appropriately referred to a
clinical geneticist (approximately 15–30 %) [6, 17, 23, 24].
To adequately document family history and to increase
the detection of persons with a risk of familial or hereditary
cancer, several tools have been developed. These range
from paper or digital questionnaires to structured inter-
views [25–29]. However, for its use in daily practice no
online self-administered family history tool exists for
identifying persons with an increased risk of CRC. We
developed and validated a new, self-administered online
questionnaire to document family history, to facilitate the




Our questionnaire was built on the criteria for referral to a
clinical geneticist or gastroenterologist, as formulated in
the Dutch national guideline on hereditary CRC [11].
These criteria are based on the internationally used
Amsterdam and Revised Bethesda criteria for the detection
of Lynch syndrome [30–32]. Criteria for familial CRC are
also formulated in the guideline, as well as criteria for a
screening colonoscopy for persons, who have a CRC
family history that does not meet the criteria for familial
CRC or Lynch syndrome. For familial CRC as well as for
patients with an indication for a single colonoscopy, a re-
ferral to a clinical geneticist is not indicated, but colono-
scopy screening or surveillance recommendations are
made.
Both the patient’s cancer history as well as the cancer
history of first and second degree relatives are system-
atically queried in the questionnaire, by using conditional
questions about affected as well as non-affected relatives.
An example of the questions can be found in Fig. 1. We
mainly focused on CRC and Lynch syndrome associated
tumors (LSAT), but people were asked to note all cancer
types that occurred in their families. Carcinoma of the
endometrium, stomach, small intestines, pancreas, bile
ducts, renal pelvis, ureters, ovaries, brain and carcinoma or
adenoma of the sebaceous gland were considered LSAT
[11].
Based on the questionnaire responses, a referral decision
can be made, according to the criteria mentioned earlier.
Several small adaptations were made to these criteria for
making referral decisions (Tables 1, 2, 3). As the guideline
referral criteria do not differentiate between maternal and
paternal lineage, we only referred patients with multiple
relatives with CRC or LSAT if these relatives were from
the same lineage in order to increase specificity. In case a
relative had a synchronous or metachronous CRC or LSAT
we counted this as two relatives with CRC or LSAT, to
compromise for the fact that the occurrence of a syn-
chronous or metachronous CRC or LSAT in relatives is not
incorporated in the Dutch referral criteria despite the in-
creased risk of Lynch syndrome in these situations. We
also referred patients with an LSAT and with two first or
second degree relatives with CRC or LSAT, all younger
than 70 years and patients with CRC younger than 70 years
with a first or second degree relative with CRC younger
than 70 years. We did not implement criteria that we
considered too medically detailed for a patient, such as
‘having a first degree relative with a microsatellite instable
CRC’. If patients had a relative with cancer diagnosed at an
unknown age, we assumed an age range between 50 and
70 years, in order not to miss any patients at risk.
During the development phase of the questionnaire
health care professionals (gastroenterologists, clinical ge-
neticists) commented on several versions, to improve
content validity. Subsequently, a preliminary version was
pilot-tested on ten consenting patients. If questions were
found to be unclear or irrelevant, they were removed or
adapted. The revised version of the questionnaire was in-
troduced in July 2013.
The burden for the responder was kept low by means of
simple, short and distinct questions. All but one question
were provided with bullet-point answers. If a cancer type
was not mentioned in the bullet-point answers, an open text
box could be filled out with the appropriate cancer type.
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The questionnaire consists of conditional questions to
avoid irrelevant questions. This results in a minimum
number of 13 and a maximum number of 117 questions to
be answered.
Questionnaire validation
We evaluated the validity and inter-observer agreement of
the online questionnaire, using the quality criteria of the
Scientific Advisory Committee of the Medical Outcomes
Trust [33]. This evaluation was conducted between July
2013 and June 2014 in Amsterdam, the Netherlands. A
total of 150 patients referred to an independent primary
center for colonoscopy (Procolo Amsterdam) were invited
to participate. Reasons for referral consisted of rectal blood
loss, change in bowel habits, surveillance after polypecto-
my or CRC, a familial risk of CRC or a positive fecal
immunochemical test.
Validity was evaluated in two phases. The first valida-
tion phase was conducted between July 2013 and October
2013. Fifty patients participated. Excluded were those not
having access to email or internet, unable to speak or read
Dutch, and those below 18. Eligible patients received a
telephone call in which we explained the purpose of the
study and invited them to participate. A personal login
code was then provided and a link to the online version of
the questionnaire was sent per email.
All study participants were scheduled for an appoint-
ment with a registered genetic counselor, who had fulfilled
a nationally accredited training in genetic counseling.
Participants were asked to fill in the questionnaire before
this appointment, which took place an hour before the
scheduled colonoscopy. If necessary, one email reminder
was sent.
At the appointment the genetic counselor drew a cancer
pedigree. This counselor did not have access to the ques-
tionnaire responses. Two researchers subsequently decided
individually whether a patient had to be referred to a
clinical geneticist based on data from the pedigree as well
as on questionnaire data by using the before mentioned
criteria. Hereafter, for each patient the agreement between
referral advice for both family histories was assessed. Only
patients with a referral advice based on the pedigree were
referred, as this was considered the reference standard.
After the first validation phase, a second validation
phase was started. The main objective of this second phase
was to evaluate validity of the questionnaire in a larger
group. We wanted to evaluate feasibility and performance
in subgroups defined by health literacy, nationality, native
language and educational level. Health literacy was
bFig. 1 Screenshots of the questionnaire
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measured using three validated questions [34], each scored
between 0 and 4. Sum scores are divided by 3 and scores
higher than 2 were considered to reflect inadequate health
literacy [34, 35]. Feasibility was further assessed by mea-
suring the required amount of time needed to complete the
questionnaire.
Hundred patients were invited for the second validation
phase. In- and exclusion criteria were similar to the criteria
in the first validation phase, except for age. To facilitate
future introduction of the questionnaire in the national fecal
immunochemical test based CRC screening program, an
age range of 55–75 years was chosen, similar to the
screening program. Patients were invited comparable to the
first phase procedure. Reasons for eventual non-participa-
tion were recorded.
After completing the questionnaire, a trained re-
searcher repeated all questions in a scripted telephone
interview with the participant, several days before the
scheduled colonoscopy. After the telephone interview
referral decisions were made based on both sets of re-
sponses, by two researchers. Discrepancies between
questionnaire answers and telephone answers were
evaluated. If a discrepancy was found in referral advice,
the advice based on the telephone interview was con-
sidered the reference standard and therefore only people
with a referral indication based on the telephone inter-
view were referred.
We evaluated the reproducibility of all referral deci-
sions based on the questionnaires, the full pedigree data
and the telephone interview, in terms of the inter-observer
agreement.
Statistical analysis
We compared referral decisions based on questionnaire
data against decisions for the same patients based on full
pedigree and telephone interview data. We considered the
latter two to be the clinical reference standard, and ex-
pressed results as questionnaire sensitivity and specificity,
with corresponding 95 % confidence intervals. The ques-
tionnaire sensitivity expresses what proportion of persons
with a clinical referral based on full pedigree or telephone
interview data would have been referred based on ques-
tionnaire responses. Specificity expresses the proportion
Table 1 Referral criteria for Lynch syndrome
A patient with colorectal cancer or endometrial cancer\50 years
A healthy person with a first degree relative with colorectal cancer or endometrial cancer\50 years
A healthy person with a family member with a known mismatch repair mutation
A healthy person with at least three first or second degree relatives with colorectal cancer or a Lynch syndrome associated tumora, all
diagnosed\70 yearsb
A colorectal cancer patient with a synchronous or metachronous colorectal cancer\70 years
A colorectal cancer patient with a synchronous or metachronous Lynch syndrome associated tumora\70 years
A colorectal cancer patient with a first degree relative with colorectal cancer or a Lynch syndrome associated tumora\50 years
A patient with colorectal cancer or a Lynch syndrome associated tumora with at least two first or second degree relatives with colorectal
cancer or a Lynch syndrome associated tumora, all diagnosed\70 yearsb
a Lynch syndrome associated tumors: carcinoma of the endometrium, stomach, small intestines, pancreas, bile ducts, renal pelvis, ureters,
ovaries, brain and carcinoma or adenoma of the sebaceous gland
b Family members must all be genetically related (paternal or maternal lineage)
Table 2 Referral criteria for familial colorectal cancer
A healthy person with two first degree relatives with colorectal cancer 50–70 yearsa
A healthy person with a first degree relative with colorectal cancer 50–70 years and a second degree relative with colorectal cancer
\70 yearsa
A colorectal cancer patient with a first degree relative with colorectal cancer both 50–70 years
A colorectal cancer patient 50–70 years and a second degree relative with colorectal cancer\70 years
a Family members must all be genetically related (paternal or maternal lineage)
Table 3 Referral criteria for a single colonoscopya
A person with two first degree relatives with colorectal cancer[70 yearsb
a If criteria are met a single colonoscopy at the age of 65 years will be offered
b Family members must all be genetically related (paternal or maternal lineage)
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not referred to a genetics specialist or gastroenterologist
based on pedigree or telephone interview data, correctly
identified as such based on questionnaire data.
Inter-observer agreement in referral decision was ex-
pressed in terms of percentage agreement between two
researchers and using Cohen’s j coefficient, defined as the
coefficient of agreement corrected for chance. A j-value
\0.20 was regarded as poor agreement; 0.21–0.40 as fair
agreement; 0.41–0.60 as moderate agreement; 0.61–0.80 as
good agreement and[0.81 as very good agreement. All
statistical analyses were performed using SPSS statistics
version 21.
Ethical approval
This study was approved by the institutional review board
of the academic medical center in Amsterdam, the
Netherlands. The introduction of the questionnaire was
considered a part of standard health care; additional ap-
proval or informed consent were not required according to
Dutch law. Use of the online questionnaire was considered
safe as all answers were collected anonymously and could
only be linked to a patient with a secured key document.




Mean age of the 50 participants in the first validation phase
was 57 years (standard deviation 11, range 35–78); 32
(64 %) were female. According to the pedigree data, nine
patients had a suspicion of Lynch syndrome, one patient
fulfilled the criteria of familial CRC and no persons ful-
filled the criteria for a single colonoscopy.
The sensitivity of the questionnaire was 90 % (95 % CI
55–98 %), for a specificity of 98 % (95 % CI 87–100 %)
when compared to the pedigree (Table 4). All patients
qualifying for referral according to the pedigree data were
also detected through the questionnaire, except for one
patient with suspected Lynch syndrome. In the pedigree of
this patient, for an unknown reason, no age was mentioned
for two second degree relatives with a LSAT, whereas the
patient had filled out a cancer diagnosis age ‘[70’ in the
questionnaire. As we considered an unknown or not re-
ported age as an age ‘50–70’ this resulted in a referral,
based on the pedigree data, but not on the questionnaire
data.
In contrast, one patient who did not qualify for referral
based on the pedigree data did have a referral indication
based on the questionnaire. This patient had indicated in
the questionnaire that a first degree relative had cervical
cancer as well as endometrial cancer, whereas in the
pedigree only cervical cancer was noted.
In 47 patients separate questions were answered differ-
ently in the questionnaire, compared to the pedigree an-
swers. The most common discrepancy was found in
answers to the questions how many second degree relatives
were affected with CRC or with other cancer types. In
many cases the answer to the questionnaire indicated that
the number of affected relatives was ‘unknown’, whereas
in the pedigree matching relatives were marked as ‘not
affected’. This did not change referral decisions, as we
considered ‘unknown’ equivalent to zero persons affected.
The second most common discrepancy was found in the
observation that participants reported different numbers of
affected second degree relatives in the questionnaire
compared to pedigree data (for instance 1 vs. 2 affected
second degree relatives in respectively the questionnaire
and pedigree of a single patient). In most cases this con-
sisted of cancer types other than CRC or LSAT and this did
not change referral indications. Discrepancies were also
seen in age of cancer diagnosis, cancer type, existence of a
hereditary cancer syndrome, having undergone previous
genetic tests and having polyps. This did not change re-
ferral indications except for the two before mentioned
situations.
An inter-observer agreement of 100 % was achieved for
referral decisions performed by the two researchers, for the
questionnaire as well as for the pedigree data, leading to a
Cohen’s j of 1.
After this first validation phase, small adaptations were
made. We added a question to find out if an affected
grandparent was from paternal or maternal lineage. A
question about the existence of more than ten polyps was
removed, as patients found it difficult to estimate the exact
number of detected polyps.
Second validation phase
Between March 2014 and June 2014 the second validation
phase was performed. Twenty-two eligible patients de-
clined the invitation to participate; one patient did not want
to participate as she was already diagnosed with familial
CRC before inclusion, one patient had a family conflict,
one patient was dyslectic, one patient did not participate for
an unknown reason, and 18 patients did not have the ability
to get online. Enrollment was continued until 100 patients
were included.
Median age of participants was 66 years (interquartile
range 60–71, range 55–75); 44 (44 %) were female, 93
(93 %) were Dutch and the native language was Dutch for
95 (95 %). Health literacy was considered adequate in all
participants and educational level was low in most of
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them (43 %). Median duration to complete the question-
naire was 7 min (interquartile range 5–10, range 3–20).
The mean number of answered questions was 27 (standard
deviation 5, range 15–41). More details can be found in
Table 5.
The sensitivity of questionnaire-based referral decisions
was 100 % (95 % CI 63–100 %) at a specificity of 97 %
(95 % CI 91–99 %) (Table 6). According to the question-
naire data, eight patients had a Lynch syndrome suspicion,
two patients had familial CRC and one patient had an
indication for a single colonoscopy.
After the telephone verification, it became clear that
three of eight Lynch syndrome suspected patients did not
have a Lynch syndrome suspicion. Referral decisions for
familial CRC and single colonoscopies did not change after
the telephone interview.
The first false-positive Lynch syndrome referral con-
cerned a participant who had filled out that her mother had
CRC and ovarian cancer, at an age between 50 and
70 years. In the telephone interview this patient said that
her mother had ovarian cancer that had ‘spread throughout
the abdomen’ and existence of CRC was not confirmed.
The second false-positive referral concerned a par-
ticipant who had indicated in the questionnaire that a
second degree relative had been diagnosed with endome-
trial cancer at an age younger than 50. In the telephone
interview he explained that it most likely involved cervical
cancer, which changed the referral indication.
Table 4 Referrals in the first validation phase with 50 participants
Referral indication Questionnaire (n) Pedigree
(n)
False-negative (n) False-positive (n) Sensitivity
(%, 95 % CI)
Specificity
(%, 95 % CI)
Lynch syndrome 9 9 1 1 90 (55–98) 98 (87–100)
Familial colorectal cancer 1 1 0 0
Single colonoscopy 0 0 0 0
Table 5 Characteristics of
participants in the second
validation phase
Participants, n 100





Adequate, n (%) 100 (100)
Inadequate, n (%) 0 (0)




Native language, n (%)
Dutch 95 (95)
Other 5 (5)




Table 6 Referrals in the second validation phase with 100 participants
Referral indication Questionnaire (n) Phone
interview (n)
False-negative (n) False-positive (n) Sensitivity
(%, 95 % CI)
Specificity
(%, 95 % CI)
Lynch syndrome 8 5 0 3 100 (63–100) 97 (91–99)
Familial colorectal cancer 2 2 0 0
Single colonoscopy 1 1 0 0
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The third false-positive referral was explained by a
participant who had filled out that she had three second
degree relatives with CRC at an unknown age. In the
telephone interview she explained that she had uninten-
tionally given incorrect answers, but she had not been able
to change those. In two cases patients were referred to a
clinical geneticist according to the questionnaire data as
well as the telephone data, but the exact reason for referral
had changed after the telephone interview.
Forty-six participants provided different answers in the
telephone interview, which only led to different referral
indications in the three above mentioned cases. Most of the
other different answers were related to the number of
second degree relatives with any kind of cancer.
An inter-observer agreement of 100 % was achieved for
referral indications based on the questionnaire data, per-
formed by two researchers, leading to a Cohen’s j of 1.
Discussion
We developed and validated an online questionnaire to
document familial cancer history, in order to facilitate the
detection of patients with a suspicion of Lynch syndrome,
familial CRC and patients with a CRC family history who
qualify for a single colonoscopy. In a two-phase validation
process we observed that this questionnaire has a high
sensitivity and specificity for detecting an indication for
referral to a clinical geneticist or gastroenterologist, com-
pared to referral decisions based on pedigree data collected
by a genetic counselor. In the second validation phase data
were verified in a telephone interview, with similarly high
sensitivity and specificity. Risk assessment based on the
given answers in the questionnaire showed a very good
inter-observer agreement.
Looking into more detail, there was only one false-
negative referral, which was probably due to the accidental
non-reporting of the ages of affected family members in the
pedigree. False-positive referrals were mainly due to par-
ticipants’ unawareness of the difference between endome-
trial or cervical cancer, which we tried to remedy by adding
a textual explanation of cervical cancer in the final
questionnaire.
As expected, the proportion of patients that had to be
referred to a clinical geneticist or gastroenterologist in our
study group was higher than the proportion of patients in
the general population assumed to have an increased risk of
familial or hereditary CRC: 12 % (18/150) versus 2–4 %
[5, 37]. This could be explained by the fact that our study
group included patients referred for colonoscopy, including
referrals for a family history of CRC. As such, this could
have also affected the performance of the tool. Unfortu-
nately, outcomes after referral to a clinical geneticist could
not be included in this study report, as not all genetic re-
sults were available at the time of our analyses.
Several tools have been previously proposed to docu-
ment family history and to increase the detection of pa-
tients with a risk of familial or hereditary CRC, ranging
from paper or digital questionnaires to structured inter-
views [10, 25–29, 38, 39]. However, most of these tools did
not take familial CRC into account and a full family history
was not documented. A tool that documents the family
history and which can also be used to calculate the risk of
several CRC syndromes is therefore preferable.
We believe online questionnaires are to be preferred
over paper questionnaires as they are easier and less ex-
pensive to use and can be used on a large scale [25, 38, 40,
41]. In several studies self-administered answers in online
questionnaires were shown not to differ from answers to
paper questionnaires [42, 43]. Another benefit of a self-
administered online tool is the possibility to fill in the
questionnaire at home at any preferred time and thereby
saving consulting time at a physician. In case an answer is
unknown, the participant can easily contact a family
member to collect reliable data, which could potentially
increase sensitivity [41]. The structured way of asking
questions about relatives, using conditional questions,
cannot be efficiently done in a paper questionnaire as this
would result in a long and unclear instrument.
Most studies that validated online tools for collecting
family history details with a focus on detecting familial
CRC and Lynch syndrome did not compare the family
history with a reference standard [25, 28, 29, 39]. In the
first validation phase we used a pedigree drawn by an ex-
perienced genetic counselor for the comparison of the
collected family history. In a recent Australian study a
sensitivity of 76 % and a specificity of 92 % were reported
for detecting patients with a familial risk of CRC when a
paper based tool, with self-administered answers, was
compared against pedigree data [29]. These estimates are
lower than in our study and could possibly be explained by
the fact that they did not systemically query the family
history and different criteria for an increased familial risk
might have been used. In another study self-administered
family history details were compared to pre-existent med-
ical chart information [39]. A geneticist compared the re-
sults and determined referral indications, but no pedigree
was drawn.
In our study we tried to identify persons with Lynch
syndrome as well as individuals with familial CRC [11].
This aim differs from that of frequently used digital tools
that only identify persons at a risk for Lynch syndrome,
such as the PREMM1,2,6 and MMRpro models [10]. A
recent Dutch study used criteria similar to ours and focused
on Lynch syndrome as well as familial CRC [25]. It
showed a sensitivity of 91 % for their online referral test,
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but this was only based on detecting Lynch syndrome
mutation carriers in CRC patients. Sensitivity was 73 % for
detecting all affected and non-affected mutation carriers.
Specificity was not assessed and no comparison was made
with a tailor-made pedigree. Sensitivity and specificity in
detecting familial CRC were not reported. Compared to
their tool more extra-colonic LSAT were included in our
referral criteria and the presence of such tumors at an age
above 50 was also taken into account, which possibly in-
creased sensitivity of our tool.
We are also aware of study limitations, most of which
involve the accuracy of the family history collection. We
are aware that we did not perform a test–retest evaluation
as part of the validation process, but it is likely that such an
evaluation would be influenced by the conversation with a
genetic counselor and by the telephone verification.
We found a proportion of (sub-)questions that were
answered differently at the pedigree or at the telephone
verification. This would possibly also occur in case patients
had two pedigrees drawn within a short time period and is
therefore difficult to avoid in clinical practice [44]. In our
study the differently answered questions did not change
referral indications in most cases.
Additionally, the questionnaire responses in the second
validation phase were not compared to a pedigree drawn by
a genetic counselor, but to responses in a scripted tele-
phone interview instead and the performance of the trained
researcher was not compared to that of a genetic counselor.
In several other studies a similar comparison was made
with data from medical charts or data collected by trained
researchers [6, 45]. We believe that in clinical practice a
family history can and probably should be documented by
any physician, and not exclusively by genetic specialists
despite the known shortcomings [19, 20]. As our ques-
tionnaire systematically queries all first and second degree
relatives and all cancer types, we think that any physician
should be capable of collecting a complete family history
using this questionnaire.
Another difficulty with family history collection is the
fact that family history was quite often unknown regarding
certain relatives. This mostly involved second degree
relatives, which is a known problem [41, 44]. As it is im-
possible to verify all unknown information, we consider
this an inevitable issue. We advised participants to contact
relatives in case of uncertainties, which is stimulated by
allowing people to pause the completion of the question-
naire. Therefore, we believe that we created a way to
achieve optimal circumstances for complete information
collection.
Even after complete information collection, not all pa-
tients at risk will be identified, since the current referral
criteria do not detect all patients with a hereditary CRC
syndrome [25]. The aim of our study was to validate the
accuracy of an online self-administered family history tool,
not the referral criteria themselves.
Several limitations regarding the studied participants
can be mentioned too. In our study group health literacy
was considered sufficient in all participants; most people
were native Dutch speakers, educational levels varied and
in the second validation phase there was an age restriction.
We do not yet know how well this questionnaire will
perform in non-native speakers and in people with more
limited health literacy. As no age restriction was used in
the first validation phase, we believe this questionnaire can
also be used in age categories other than 55–75 years.
Additionally, we selected participants that were referred to
a center for colonoscopy and therefore it is questionable if
the questionnaire can be used for non-referred persons. As
indications for referral varied amongst participants this
selection bias seems limited. And unfortunately, several
people were not able to participate due to limited access to
internet. Help from a family member or friend could avoid
this problem. And as the population is increasingly getting
familiar with computers and internet we think this problem
will eventually be minimized.
Our questionnaire could be embedded in several set-
tings, ranging from primary care clinics, outpatient clinics
and population screening. As the second validation phase
was conducted in a population that could represent the
population participating in the nationwide fecal immuno-
chemical test based CRC screening program, it could be
used for that purpose. To reach a wider population, the test
should be validated in different languages and in patients
with different degrees of health literacy. If used as a
screening tool, answers do not necessarily have to be ver-
ified since a sensitivity and specificity that are not perfectly
accurate are usually accepted in screening circumstances.
However, in individual cases, such as for CRC patients,
answers need to be verified. An automatic risk assessment
based on the answers can help to determine referral indi-
cations and this is currently being developed by our re-
search group. The most efficient way of using this tool
needs to be further determined.
In conclusion, this online questionnaire for the detection
of persons at risk of familial or hereditary CRC syndromes
seems to be an accurate tool that can be easily implemented
in several health care situations in order to increase the
detection of patients with familial CRC and Lynch syn-
drome. This will eventually result in appropriate treatment
and surveillance recommendations for many persons at
risk.
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